ArticleInfectious diseases of poverty2026
Impact of risk adjustment for drug-resistant types on tuberculosis patients' outcomes under China's innovative payment methods: a quasi-experimental study design.
Article in Infectious diseases of poverty, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTreating drug-resistant tuberculosis (DR-TB) is clinically complex and economically burdensome compared to drug-susceptible tuberculosis (DS-TB). China's diagnosis-intervention packet payment system initially omitted risk adjustment for drug resistance. In 2022, a diagnosis-intervention packet (DIP)-pilot city implemented such adjustment, establishing distinct reimbursement standards for DR-TB and DS-TB. This study aimed to assess the impact of this DR-type risk adjustment on medical expenditures, treatment efficiency, and care quality for TB patients.
methodsA quasi-experimental difference-in-differences design was employed, involving 8465 TB patients from June 2021 to December 2023. Linear regression was performed with time and treat fixed effects and the interaction term between time and treat. Subgroup analyses for DR-TB and DS-TB patients were conducted.
resultsUnder the DIP system, risk adjustment led to marginally significant reductions in inpatient expenditure per hospitalization [β = - 151.14, P = 0.065; 95% confidence interval (CI) for difference in proportions: - 311.66, 9.38] and in annual total inpatient expenditure per patient (β = - 200.58, P = 0.078, 95% CI - 423.26, 22.10) for all TB patients. It also resulted in significant reductions in inpatient out-of-pocket per hospitalization (β = - 257.51, P < 0.001, 95% CI - 316.20, - 198.81), annual total inpatient out-of-pocket per patient (β = - 266.78, P < 0.001, 95% CI - 342.02, - 191.53), inpatient length of stay per hospitalization (β = - 3.58, P < 0.001, 95% CI - 4.53, - 2.62), and annual total length of stay per patient (β = - 3.21, P < 0.001, 95% CI - 4.50, - 1.92). For DR-TB patients, all outcome measures in expenditures, efficiency, or care quality showed P > 0.1, indicating no significant changes. For DS-TB patients, measures of expenditures and efficiency showed P < 0.1, supporting significant or marginally significant reductions.
conclusionsThe DR-type risk adjustment policy under China's diagnosis-intervention packet system proved effective in optimizing resource use and enhancing efficiency, particularly for DS-TB patients, while preserving care quality for DR-TB patients. These findings demonstrate the value of tailored risk adjustment within payment frameworks for heterogeneous diseases like tuberculosis, providing crucial evidence for optimizing TB care and implementing effective payment reforms in China and similar settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.